Additional file 1: of Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Table S1 describes the rates of remaining on drug, switching, and discontinuing without starting a new biologic in the TCZ and ABA groups before and after match. Table S2 presents the distribution of prednisone dose increases and decreases between the matched TCA and ABA initiators based on the baseline prednisone usage. Table S3 presents rates of discontinuation and initiation of cDMARDs over the 6-month follow-up. (DOCX 14 kb